| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(2 years from now) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(5 years from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(6 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(3 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
Baxdela is owned by Melinta.
Baxdela contains Delafloxacin Meglumine.
Baxdela has a total of 13 drug patents out of which 0 drug patents have expired.
Baxdela was authorised for market use on 19 June, 2017.
Baxdela is available in powder;intravenous dosage forms.
Baxdela can be used as treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults.
Drug patent challenges can be filed against Baxdela from 2026-06-19.
The generics of Baxdela are possible to be released after 27 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 19, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 2026-06-19
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: POWDER;INTRAVENOUS
BAXDELA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic